Literature DB >> 31152872

De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.

Mohammed Qintar1, Taishi Hirai2, Suzanne V Arnold1, Justin Sheehy1, James Sapontis3, Phil Jones1, Yuanyuan Tang4, William Lombardi5, Dimitri Karmpaliotis6, Jeffery Moses6, Christian Patterson4, William J Nicholson7, David J Cohen1, John A Spertus1, J Aaron Grantham1, Adam C Salisbury8.   

Abstract

BACKGROUND: Successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI) can markedly reduce angina symptom burden, but many patients often remain on multiple antianginal medications (AAMs) after the procedure. It is unclear when, or if, AAMs can be de-escalated to prevent adverse effects or limit polypharmacy. We examined the association of de-escalation of AAMs after CTO PCI with long-term health status.
METHODS: In a 12-center registry of consecutive CTO PCI patients, health status was assessed at 6 months after successful CTO PCI with the Seattle Angina Questionnaire and the Rose Dyspnea Scale. Among patients with technical CTO PCI success, we examined the association of AAM de-escalation with 6-month health status using multivariable models adjusting for revascularization completeness and predicted risk of post-PCI angina (using a validated risk model). We also examined predictors and variability of AAMs de-escalation.
RESULTS: Of 669 patients with technical success of CTO PCI, AAMs were de-escalated in 276 (35.9%) patients at 1 month. Patients with AAM de-escalation reported similar angina and dyspnea rates at 6 months compared with those whose AAMs were reduced (any angina: 22.5% vs 20%, P = .43; any dyspnea: 51.8% vs 50.1%, P = .40). In a multivariable model adjusting for complete revascularization and predicted risk of post-PCI angina, de-escalation of AAMs at 1 month was not associated with an increased risk of angina, dyspnea, or worse health status at 6 months.
CONCLUSIONS: Among patients with successful CTO PCI, de-escalation of AAMs occurred in about one-third of patients at 1 month and was not associated with worse long-term health status.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31152872      PMCID: PMC7147489          DOI: 10.1016/j.ahj.2019.04.013

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  32 in total

1.  Cardiovascular survey methods.

Authors:  G A Rose; H Blackburn
Journal:  Monogr Ser World Health Organ       Date:  1968

2.  Development and validation of a short version of the Seattle angina questionnaire.

Authors:  Paul S Chan; Philip G Jones; Suzanne A Arnold; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-09-02

3.  Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.

Authors:  John A Spertus; David J Maron; David J Cohen; Paul Kolm; Pam Hartigan; William S Weintraub; Daniel S Berman; Koon K Teo; Leslee J Shaw; Steven P Sedlis; Merril Knudtson; Mihaela Aslan; Marcin Dada; William E Boden; G B John Mancini
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-07-09

4.  Quality of life benefits of percutaneous coronary intervention for chronic occlusions.

Authors:  David M Safley; J Aaron Grantham; Jason Hatch; Philip G Jones; John A Spertus
Journal:  Catheter Cardiovasc Interv       Date:  2013-12-19       Impact factor: 2.692

5.  Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial.

Authors:  Suzanne V Arnold; Mikhail Kosiborod; Yan Li; Philip G Jones; Patrick Yue; Luiz Belardinelli; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-09-23

6.  Derivation and validation of a risk standardization model for benchmarking hospital performance for health-related quality of life outcomes after acute myocardial infarction.

Authors:  Suzanne V Arnold; Frederick A Masoudi; John S Rumsfeld; Yan Li; Philip G Jones; John A Spertus
Journal:  Circulation       Date:  2013-10-25       Impact factor: 29.690

7.  Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.

Authors:  Karen P Alexander; Giora Weisz; Kristi Prather; Stefan James; Daniel B Mark; Kevin J Anstrom; Linda Davidson-Ray; Adam Witkowski; Angel J Mulkay; Anna Osmukhina; Ramin Farzaneh-Far; Ori Ben-Yehuda; Gregg W Stone; E Magnus Ohman
Journal:  Circulation       Date:  2015-11-10       Impact factor: 29.690

8.  Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.

Authors:  Suzanne V Arnold; David A Morrow; Yang Lei; David J Cohen; Elizabeth M Mahoney; Eugene Braunwald; Paul S Chan
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-06-02

Review 9.  Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information.

Authors:  Anthony J Barron; Nabeela Zaman; Graham D Cole; Roland Wensel; Darlington O Okonko; Darrel P Francis
Journal:  Int J Cardiol       Date:  2013-06-21       Impact factor: 4.164

10.  The Impact of De-escalation of Antianginal Medications on Health Status After Percutaneous Coronary Intervention.

Authors:  Mohammed Qintar; Arooge Towheed; Fengming Tang; Adam C Salisbury; P Michael Ho; J Aaron Grantham; John A Spertus; Suzanne V Arnold
Journal:  J Am Heart Assoc       Date:  2017-10-20       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.